Short Interest in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Decreases By 25.7%

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,600 shares, a decrease of 25.7% from the August 31st total of 3,500 shares. Based on an average daily volume of 24,800 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

STRATA Skin Sciences Stock Down 7.8 %

NASDAQ:SSKN traded down $0.25 on Friday, hitting $2.95. The stock had a trading volume of 19,090 shares, compared to its average volume of 11,680. The company has a quick ratio of 0.92, a current ratio of 1.14 and a debt-to-equity ratio of 1.59. STRATA Skin Sciences has a 52 week low of $2.51 and a 52 week high of $7.10. The business’s fifty day moving average is $3.14 and its 200 day moving average is $3.71. The company has a market cap of $10.35 million, a PE ratio of -0.89 and a beta of 1.37.

STRATA Skin Sciences (NASDAQ:SSKN) last issued its earnings results on Wednesday, August 14th. The medical device company reported ($0.03) earnings per share for the quarter. STRATA Skin Sciences had a negative return on equity of 50.45% and a negative net margin of 25.40%. The firm had revenue of $8.44 million for the quarter. On average, equities research analysts expect that STRATA Skin Sciences will post -1 EPS for the current fiscal year.

Insider Activity at STRATA Skin Sciences

In other STRATA Skin Sciences news, Director Uri Geiger bought 230,573 shares of the stock in a transaction on Monday, July 15th. The stock was acquired at an average cost of $3.14 per share, for a total transaction of $723,999.22. Following the completion of the acquisition, the director now owns 1,441,835 shares in the company, valued at approximately $4,527,361.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Dolev Rafaeli acquired 19,100 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were bought at an average price of $3.14 per share, with a total value of $59,974.00. Following the transaction, the chief executive officer now directly owns 143,156 shares of the company’s stock, valued at $449,509.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Uri Geiger bought 230,573 shares of STRATA Skin Sciences stock in a transaction dated Monday, July 15th. The stock was purchased at an average price of $3.14 per share, with a total value of $723,999.22. Following the completion of the purchase, the director now owns 1,441,835 shares in the company, valued at $4,527,361.90. The disclosure for this purchase can be found here. 40.43% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in STRATA Skin Sciences stock. Azzad Asset Management Inc. ADV increased its holdings in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) by 289.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,000 shares of the medical device company’s stock after acquiring an additional 49,800 shares during the period. Azzad Asset Management Inc. ADV owned about 0.19% of STRATA Skin Sciences worth $25,000 at the end of the most recent quarter. 32.43% of the stock is currently owned by institutional investors.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.